FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA AI Moves Raise Questions: Attorneys

[ Price : $8.95]

Three Akin attorneys say regulated industry continues to have questions about FDA actions in launching an internal artificial inte...

Panel Votes Down GSK Multiple Myeloma Drug

[ Price : $8.95]

FDAs Oncologic Drugs Advisory Committee votes against approving GSKs BLA for Blenrep (belantamab mafodotin) for treating adults wi...

Dexcom Recalls Dexcom Glucose Monitor Receivers

[ Price : $8.95]

Dexcom recalls certain Dexcom G6, G7, ONE, and ONE+ glucose monitoring receivers because a speaker problem may prevent an alert fr...

Investigate GLP-1 Online Marketing: Blackburn

[ Price : $8.95]

Sen. Marsha Blackburn and Tennessee attorney general Jonathan Skrmetti call on the Federal Trade Commission to open an investigati...

FDA Warns Firm Marketing Blood Pressure Estimator

[ Price : $8.95]

FDA warns Boston, MA-based Whoop that it is illegally marketing an unapproved medical device that estimates blood pressure, despit...

Anselamimab Trial Misses Primary Endpoint in Amyloidosis

[ Price : $8.95]

A Phase 3 clinical trial evaluating Alexions anselamimab for light chain amyloidosis fails to meet its primary endpoint, but shows...

New Orphan Product Grant Funding Opportunity

[ Price : $8.95]

FDA releases a funding opportunity for natural history studies to advance product development in rare diseases and conditions.

7 Observations in Natco Pharma FDA-483

[ Price : $8.95]

FDA releases the form FDA-483 with seven observations from an inspection at Indias Natco Pharma.

Guide to Characterize Combination Cancer Drugs

[ Price : $8.95]

FDA publishes a draft guidance on characterizing the effects of some oncology drugs when used in combination with other drugs.

Fast Track Status for Zenith NUT Cancer Drug

[ Price : $8.95]

FDA grants Zenith Epigenetics a fast-track designation for its ZEN-3694 and its use for treating metastatic or unresectable NUT ca...